Karneboge, Jonas ORCID: 0009-0000-9272-6535, Haberstroh, Julia ORCID: 0000-0003-3133-011X, Geschke, Katharina ORCID: 0000-0001-7311-0049, Perry, Julia ORCID: 0000-0001-8112-0298, Radenbach, Katrin ORCID: 0009-0005-2409-6582, Jessen, Frank ORCID: 0000-0003-1067-2102 and Rostamzadeh, Ayda ORCID: 0000-0001-5189-134X (2025). Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent. Alzheimer's & Dementia, 21 (1). pp. 1-8. Wiley. ISSN 1552-5260

[thumbnail of Alzheimer s Dementia - 2025 - Karneboge - Facing the new diagnostic and treatment options of Alzheimer s disease The.pdf] PDF
Alzheimer s Dementia - 2025 - Karneboge - Facing the new diagnostic and treatment options of Alzheimer s disease The.pdf
Bereitstellung unter der CC-Lizenz: Creative Commons Attribution Non-commercial No Derivatives.

Download (305kB)
Identification Number:10.1002/alz.14204

Abstract

[Artikel-Nr.: e14204] With advances in biomarker‐based detection of Alzheimer's disease (AD) and new treatment options with disease‐modifying treatments (DMTs), we are heading toward a new conceptualization of diagnostics and therapy in the early stages of AD. Yet consensus guidelines on best clinical practices in predictive AD diagnostics are still developing. Currently, there is a knowledge gap regarding counseling and disclosure practices in early symptomatic disease stages, its implications for dementia risk estimation, and DMTs with associated risks and benefits. The crucial feature is the capacity of patients with (mild) cognitive impairment, eligible for DMTs, to consent. This perspective aims to (1) discuss the current challenges in assessing capacity to consent and (2) highlight the importance of a supported (informed) decision‐making process. Measures to facilitate informed decision‐making of patients constitute an ethical approach to enhancing the quality of care in this evolving therapeutic landscape. Highlights: This perspective: Explores biomarker‐based early symptomatic AD detection and the implications for patient care. Emphasizes supported decision‐making in DMTs for MCI and dementia patients. Discusses the need for standardized tools to assess the capacity to consent. Aligns diagnostic and treatment approaches with ethical care standards. Enhances patient autonomy in the evolving AD therapeutic landscape.

Item Type: Article
Creators:
Creators
Email
ORCID
ORCID Put Code
Karneboge, Jonas
UNSPECIFIED
UNSPECIFIED
Haberstroh, Julia
UNSPECIFIED
UNSPECIFIED
Geschke, Katharina
UNSPECIFIED
UNSPECIFIED
Perry, Julia
UNSPECIFIED
UNSPECIFIED
Radenbach, Katrin
UNSPECIFIED
UNSPECIFIED
Jessen, Frank
UNSPECIFIED
UNSPECIFIED
Rostamzadeh, Ayda
UNSPECIFIED
UNSPECIFIED
URN: urn:nbn:de:hbz:38-816385
Identification Number: 10.1002/alz.14204
Journal or Publication Title: Alzheimer's & Dementia
Volume: 21
Number: 1
Page Range: pp. 1-8
Number of Pages: 8
Date: 30 January 2025
Publisher: Wiley
ISSN: 1552-5260
Language: English
Faculty: Central Institutions / Interdisciplinary Research Centers
Faculty of Medicine
Divisions: CECAD - Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases
Faculty of Medicine > Psychiatrie und Psychotherapie > Klinik und Poliklinik für Psychiatrie und Psychotherapie
Subjects: Medical sciences Medicine
Uncontrolled Keywords:
Keywords
Language
anti-amyloid therapy ; biomarkers ; capacity to consent ; communication ; dementia risk estimation ; early diagnosis ; informed consent ; supported decision-making
English
['eprint_fieldname_oa_funders' not defined]: Publikationsfonds UzK
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/81638

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item